GLP-1s are moving the goalposts.
Groupthink. Nearly 50M US adults have now used an injectable GLP-1 drug, spawning lucrative subcategories and tough questions.
Food. “GLP-1” has become the second-most-common diet in America, with 8.5% of adults seeking protein-rich, calorie-restricted meals — a change that could cost the food industry $30B–55B by 2030, per JPMorgan.
Appearance. Plastic surgery demand is rising, led by senior “lifts” and facial fat grafting. Less-invasive, many are requesting AlloClae and Re2O—injections derived from cadaver tissue—to restore volume and skin firmness.
Fitness. GLP-1 users spend 4x more on fitness, trading up at gyms and right-sizing activewear. But activity levels often drop after starting medication, reinforcing the need for structured training programs that drive adherence.
Athletics. Global sports medicine physicians believe 12% of elite athletes take GLP-1s without a medical need. A potential unfair advantage for some sports, 44% support a ban — and WADA is still debating it.
Upbringing. Novo Nordisk’s latest trial reversed obesity for 40% of kids aged 6–12, but 44% of Gen Z/millennials feel GLP-1 culture creates negative pressure to slim down, and 72% of teens want to lose lbs without them.
Takeaway: GLP-1s have lowered national obesity, and the majority of users report feeling like a different person for the better. As adoption grows, the wellness economy will bend to—and build around—their new personas.
